{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-005892","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.262983+00:00","generated_at":"2026-06-27T02:05:45.449458+00:00","sec_items":["1.01","2.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lucid Diagnostics acquires lab assets from ResearchDx for up to $6.2M, launches LucidDx Labs; CMO resigns","bullets":["LucidDx Labs acquired licenses/assets from ResearchDx for up to $6.2M; $1.0M cash upfront, remainder contingent on license transfers and earnout.","LucidDx Labs will operate its own CLIA/CAP lab in Lake Forest, CA to perform EsoGuard testing, replacing RDx as testing provider.","LucidDx Labs entered a 3-year MSA with RDx for up to $1.8M in quarterly installments, plus lease at $71,465/month for lab space.","CMO David F. Wurtman resigned effective March 31, 2022; Brian J. deGuzman, MD (current Chief Compliance Officer) will assume duties.","Earnout payments may be made in cash or newly issued LUCD stock, not exceeding 19.99% of outstanding shares, exempt from registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-005892","json":"https://secwatch.observer/filing/0001493152-22-005892.json","markdown":"https://secwatch.observer/filing/0001493152-22-005892.md","text":"https://secwatch.observer/filing/0001493152-22-005892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315222005892/0001493152-22-005892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315222005892/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:05:45.449458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba276edc5f","claim":"David F. Wurtman resigned as Chief Medical Officer at Lucid Diagnostics Inc..","evidence_excerpt":"On March 1, 2022, David F. Wurtman, M.D. resigned from his position as Chief Medical Officer of the Company, effective as of March 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799011/000149315222005892/0001493152-22-005892-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}